Osteoclast-related genes and chemokine production

Osteoclast-related genes and chemokine production refers to the coordinated molecular program that drives the differentiation, recruitment, and bone-resorbing activity of osteoclasts, the primary cells responsible for skeletal degradation (Source: StatPearls, NBK441901). This process is primarily regulated by the RANK/RANKL/OPG signaling axis, where the binding of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) to its receptor RANK on osteoclast precursors triggers the expression of essential genes like NFATc1, Cathepsin K (CTSK), and Tartrate-resistant acid phosphatase (ACP5) (Source: UniProt, O14788; Source: PubMed, PMID: 10359548). Simultaneously, these cells produce chemokines such as CCL2 (MCP-1) and CXCL12 (SDF-1), which act as chemoattractants to recruit additional osteoclast progenitors to sites of bone remodeling, thereby amplifying the resorptive process (Source: PubMed, PMID: 25853068). Dysregulation of this genetic and secretory network is a hallmark of diseases characterized by excessive bone loss, such as osteoporosis, rheumatoid arthritis, and bone metastases (Source: PubMed, PMID: 15591248). Clinical interventions often target specific components of this system, most notably through the use of Denosumab to neutralize RANKL or bisphosphonates to inhibit osteoclast activity and survival (Source: PubChem, CID 16133850).

Other names

Osteoclastogenesis pathwayBone resorption markersOsteoclast secretomeOsteoclast-derived chemokines

Therapeutic agents modulate this process by neutralizing the RANKL ligand to prevent osteoclast maturation, inducing apoptosis in mature osteoclasts via mevalonate pathway inhibition, or inhibiting specific proteases like Cathepsin K that are essential for bone matrix degradation.